173 related articles for article (PubMed ID: 34741731)
1. Clinical and Preclinical Single-Dose Pharmacokinetics of VIR-2218, an RNAi Therapeutic Targeting HBV Infection.
Gupta SV; Fanget MC; MacLauchlin C; Clausen VA; Li J; Cloutier D; Shen L; Robbie GJ; Mogalian E
Drugs R D; 2021 Dec; 21(4):455-465. PubMed ID: 34741731
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: Results from randomized clinical trials.
Gane E; Lim YS; Kim JB; Jadhav V; Shen L; Bakardjiev AI; Huang SA; Cathcart AL; Lempp FA; Janas MM; Cloutier DJ; Kaittanis C; Sepp-Lorenzino L; Hinkle G; Taubel J; Haslett P; Milstein S; Anglero-Rodriguez YI; Hebner CM; Pang PS; Yuen MF
J Hepatol; 2023 Oct; 79(4):924-932. PubMed ID: 37290591
[TBL] [Abstract][Full Text] [Related]
3. Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial.
Yuen MF; Agarwal K; Gane EJ; Schwabe C; Ahn SH; Kim DJ; Lim YS; Cheng W; Sievert W; Visvanathan K; Ruby E; Liaw S; Yan R; Huang Q; Colonno R; Lopatin U
Lancet Gastroenterol Hepatol; 2020 Feb; 5(2):152-166. PubMed ID: 31711752
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects.
Jing S; Lin Y; Dockens R; Marchisin D; He B; Girgis IG; Chimalakonda A; Murthy B; Aras U
Dermatol Ther (Heidelb); 2023 Dec; 13(12):3153-3164. PubMed ID: 37981596
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of the Melanocortin Type 1 Receptor Agonist PL8177 After Subcutaneous Administration.
Dodd J; Jordan R; Makhlina M; Pesco Koplowitz L; Koplowitz B; Barnett K; Yang WH; Spana C
Drugs R D; 2021 Dec; 21(4):431-443. PubMed ID: 34693509
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria.
Badri P; Jiang X; Borodovsky A; Najafian N; Kim J; Clausen VA; Goel V; Habtemariam B; Robbie GJ
Clin Pharmacokinet; 2021 Mar; 60(3):365-378. PubMed ID: 33047216
[TBL] [Abstract][Full Text] [Related]
7. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
[TBL] [Abstract][Full Text] [Related]
8. A Randomized, Double-Blind, Placebo-Controlled, First-Time-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of GSK3389404 in Healthy Subjects.
Han K; Cremer J; Elston R; Oliver S; Baptiste-Brown S; Chen S; Gardiner D; Davies M; Saunders J; Hamatake R; Losos J; Leivers M; Hood S; van der Berg F; Paff M; Ritter JM; Theodore D
Clin Pharmacol Drug Dev; 2019 Aug; 8(6):790-801. PubMed ID: 30861337
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
[TBL] [Abstract][Full Text] [Related]
10. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Pharmacokinetics of the GalNAc-Conjugated Antisense Oligonucleotide GSK3389404 in Participants with Chronic Hepatitis B Infection across the Asia-Pacific Region.
Han K; Ito H; Elston R; Cremer J; Hood S; Paff M; Theodore D
Antimicrob Agents Chemother; 2023 Jan; 67(1):e0090022. PubMed ID: 36507675
[TBL] [Abstract][Full Text] [Related]
12. A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine.
Kinzler ER; Pantaleon C; Iverson M; Aigner S
Adv Ther; 2019 Sep; 36(9):2394-2401. PubMed ID: 31278694
[TBL] [Abstract][Full Text] [Related]
13. A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults.
Munjal S; Gautam A; Offman E; Brand-Schieber E; Allenby K; Fisher DM
Headache; 2016 Oct; 56(9):1455-1465. PubMed ID: 27613076
[TBL] [Abstract][Full Text] [Related]
14. A Phase 1, Randomised, Placebo-Controlled, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Cannabidiol in Fed Healthy Volunteers.
Perkins D; Butler J; Ong K; Nguyen TH; Cox S; Francis B; Mcintosh M; Lilley B
Eur J Drug Metab Pharmacokinet; 2020 Oct; 45(5):575-586. PubMed ID: 32409982
[TBL] [Abstract][Full Text] [Related]
15. A phase 1 study in healthy volunteers to investigate the safety, tolerability, and pharmacokinetics of VIR-2482: a monoclonal antibody for the prevention of severe influenza A illness.
Plotnik D; Sager JE; Aryal M; Fanget MC; Peter A; Schmid MA; Cebrik D; Mogalian E; Boundy K; Yeh WW; Griffin P; Reyes M
Antimicrob Agents Chemother; 2024 Apr; 68(4):e0127323. PubMed ID: 38376227
[TBL] [Abstract][Full Text] [Related]
16. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers.
Chien SC; Wong FA; Fowler CL; Callery-D'Amico SV; Williams RR; Nayak R; Chow AT
Antimicrob Agents Chemother; 1998 Apr; 42(4):885-8. PubMed ID: 9559801
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, safety and tolerability of single- and multiple-ascending doses of JNJ-64530440, a novel hepatitis B virus capsid assembly modulator, in healthy volunteers.
Kakuda TN; Yogaratnam JZ; Westland C; Gane EJ; Schwabe C; Vuong J; Patel M; Snoeys J; Talloen W; Lenz O; Fry J; Chanda S; van Remoortere P
Antivir Ther; 2021; 26(1-2):13-24. PubMed ID: 35485346
[TBL] [Abstract][Full Text] [Related]
18. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP3652, a Reversible Fatty Acid Amide Hydrolase Inhibitor, in Healthy, Nonelderly, Japanese Men and Elderly, Japanese Men and Women: A Randomized, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Phase I Study.
Takizawa M; Hatta T; Iitsuka H; Katashima M; Sato Y; Kuroishi K; Nagashima H
Clin Ther; 2020 May; 42(5):906-923. PubMed ID: 32456804
[TBL] [Abstract][Full Text] [Related]
19. A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects.
Crockett J; Critchley D; Tayo B; Berwaerts J; Morrison G
Epilepsia; 2020 Feb; 61(2):267-277. PubMed ID: 32012251
[TBL] [Abstract][Full Text] [Related]
20. Effects of Food Intake on the Relative Bioavailability of Amifampridine Phosphate Salt in Healthy Adults.
Haroldsen PE; Musson DG; Hanson B; Quartel A; O'Neill CA
Clin Ther; 2015 Jul; 37(7):1555-63. PubMed ID: 26101174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
